Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer~* Prior treatment with only 1 platinum based chemotherapy regimen~* Eastern Cooperative Oncology Group status of not more than 2~* Progression more than 6 months after the start of initial chemotherapy treatment~Exclusion Criteria:~* Treatment with more than 1 prior chemotherapy regimen~* Progression within 6 months after starting initial chemotherapy~* Prior exposure to anthracyclines~* Unwilling or unable to have central venous catheter~* Known clinically relevant central nervous system metastasis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOXIL + trabectedin (Type: EXPERIMENTAL): Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
- DOXIL (Type: ACTIVE_COMPARATOR): Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).